severe asthma

Behavior change to increase physical activity reduces sleep disturbances in asthma: A randomized controlled trial
P Freitas, N F Passos, A Cukier, R Carvalho-Pinto, C R Fernandes de Carvalho

European Respiratory Journal Sep 2022, 60 (suppl 66) 4207; DOI: 10.1183/13993003.congress-2022.4207
A case of excavated pneumopathy after bronchial thermoplasty
M Steger, N Khayath, M Ohana, N Migueres, C Marcot, F De Blay, N Migueres

European Respiratory Journal Sep 2022, 60 (suppl 66) 4216; DOI: 10.1183/13993003.congress-2022.4216
Metformin: A potential drug candidate to restore poor corticosteroid sensitivity in obese asthmatic patients
M To, N Honda, K Haruki, Y To

European Respiratory Journal Sep 2022, 60 (suppl 66) 4344; DOI: 10.1183/13993003.congress-2022.4344
Achievement rate and predictive factors of the deep remission to biologics in severe asthma
K Oishi, K Hamada, Y Murata, Y Yamaji, M Asami, N Edakuni, T Hirano, K Matsunaga

European Respiratory Journal Sep 2022, 60 (suppl 66) 4401; DOI: 10.1183/13993003.congress-2022.4401
Longitudinal data-driven definition of clinical asthma phenotypes in the pediatric arm of the ALLIANCE cohort
A J Hose, E Von Mutius, K F Rabe, G Hansen, M V Kopp, M J Ege

European Respiratory Journal Sep 2022, 60 (suppl 66) 4604; DOI: 10.1183/13993003.congress-2022.4604
Waning of biologic effect at end of dosing interval perceived by patients with severe asthma
J A Kroes, L H G Van Hal, L Van Dijk, S W Zielhuis, E N Van Roon, A Ten Brinke, J A Kroes

European Respiratory Journal Sep 2022, 60 (suppl 66) 4351; DOI: 10.1183/13993003.congress-2022.4351
The PARP14 inhibitor RBN-3143 suppresses lung inflammation in preclinical models
M Niepel, M Vasbinder, J Molina, B Gui, K Kunii, D Blackwell, E Mateer, J Mo, C Coutts, N Perl, K Kuplast-Barr, W Church, C Majer, L B Schenkel, K Swinger, R Abo, E Bamberg, Y Ren, L Utley, T Wigle, C Reik, A Lu, A Cheung, E Minissale, K Mceachern, V Richon, S Parasuraman, K Kuntz, H Keilhack

European Respiratory Journal Sep 2022, 60 (suppl 66) 4642; DOI: 10.1183/13993003.congress-2022.4642
Mepolizumab effectiveness in severe asthma supported by federated analysis of European SHARP data
J A Kroes, R Alfonso-Cristancho, A T Bansal, E Berret, K Bieksiene, A Bourdin, L Brussino, D Canhoto, C Cardini, G Celik, Z Csoma, B Dahlén, E Damadoğlu, K Eger, L Gauquelin, B Gemicioglu, O Goksel, S Graff, E Heffler, H B Hofstee, P Howarth, R Jakes, F Jaun, V Kalinauskaite-Zukauske, P Kopač, N Kwon, C C Loureiro, V Lozoya García, M Masoli, M Paula Rezelj, L Pérez De Llano, S Popović-Grle, D Ramos-Barbon, A Sà Sousa, K Samitas, F Schleich, C Sirena, S Skrgat, E Zervas, G Zichnalis, E H Bel, J K Sont, S Hashimoto, A Ten Brinke

European Respiratory Journal Sep 2022, 60 (suppl 66) 4340; DOI: 10.1183/13993003.congress-2022.4340
Predictors of poor disease control and impaired quality of life (QOL) in patients with severe asthma (SA) in the Wessex Severe Asthma Cohort (WSAC)
V Bataduwaarachchi, T Brown, L Wiffen, T Jones, C Barber, P Howarth, C Anoop

European Respiratory Journal Sep 2022, 60 (suppl 66) 4228; DOI: 10.1183/13993003.congress-2022.4228
International, prospective study of mepolizumab in severe asthma: REALITI-A at 2yrs
C Caruso, G W Canonica, M Patel, A Smith, M C Liu, R Alfonso-Cristancho, R G Price, R W Jakes, L Demetriou, A Valero, C Pilette, P Howarth

European Respiratory Journal Sep 2022, 60 (suppl 66) 4589; DOI: 10.1183/13993003.congress-2022.4589

Main menu

User menu

Search

severe asthma

Pages

Contact us